-
1
-
2
Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained?
منشور في 2025"…We appraised the evolution of 20 outcomes at 1, 3, 5, 7, and 9 years.…"
-
3
-
4
Characterization of Dse1 a candida albicans cells wall protein. (c2009)
منشور في 2009احصل على النص الكامل
احصل على النص الكامل
masterThesis -
5
-
6
-
7
-
8
-
9
-
10
-
11
Rescue cerclage
منشور في 2006احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل
article -
12
-
13
-
14
-
15
-
16
-
17
Durability of Cardiometabolic Outcomes Among Adolescents After Sleeve Gastrectomy: First Study with 9-Year Follow-up
منشور في 2022"…Remission rates were triglycerides, 100% (11/11) at 5 years, and 100% (1/1) at 9 years; high density lipoprotein, 89.4% (17/19) at 5 years, and 100% (3/3) at 7 years; low density lipoprotein, 71.4% (11/14) and 100% (3/3) at 5 and 7 years; total cholesterol, 70% (7/10) at 5 years, and 100% (2/2) at 9 years; uric acid, 100% (3/3) at 5 years. …"
-
18
Clinical characteristics and treatment outcomes of coats disease in a Saudi Arabian population
منشور في 2015"…Based on the Shields classification, the eyes were Stage 1 (n = 1, 1%), Stage 2A (n = 7, 7%), Stage 2B (n = 23, 24%), Stage 3A1 (n = 26, 27%), Stage 3A2 (n = 12, 12%), Stage 3B (n = 16, 17%), Stage 4 (n = 11, 11%), and Stage 5 (n = 5, 1%). …"
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل
احصل على النص الكامل
article -
19
Screening the growth inhibition mechanism of sulfate reducing bacteria by chitosan/lignosulfonate nanocomposite (CS@LS) in seawater media
منشور في 2021"…The SRBs spiked with 500 µg/mL CS@LS showed a reduction in cell viability to 1.5 × 106 MPN/mL. To assess the biosafety of the nanocomposite on the marine biota, the 72-hours acute toxicity assays using zebrafish embryo model revealed that the LC50 for the CS@LS was 103.3 µg/mL. …"
-
20
Optimum sizing of steam turbines for concentrated solar power plants
منشور في 2012احصل على النص الكامل
article